Pioneering a New Era in Cancer Treatment

Keraceuticals is revolutionizing cancer therapy with its breakthrough drug, CIDD99, which targets a previously untapped mechanism. By disrupting calcium signaling pathways, CIDD99 depletes cancer cells’ critical calcium stores in the endoplasmic reticulum, halting their energy supply and triggering apoptosis. This innovative approach selectively eradicates cancer cells while sparing healthy tissues, offering a safer, more effective alternative to traditional therapies.

With a unique mechanism of action and promising pre-clinical results across multiple cancer types, Keraceuticals is transforming the landscape of oncology treatment.